Monopar to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
04 Settembre 2024 - 2:00PM
Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage
biopharmaceutical company focused on developing innovative
treatments for cancer patients, today announced that Chandler D.
Robinson, MD, Monopar’s Chief Executive Officer, will present at
the H.C. Wainwright 26th Annual Global Investment Conference. The
Company’s presentation will be webcast beginning on Monday,
September 9, 2024 at 7:00 a.m. ET. In person one-on-one
meetings will take place at the Lotte New York Palace, NY, NY from
September 9 - 11, 2024.
About Monopar Therapeutics
Inc.
Monopar Therapeutics is a clinical-stage
radiopharmaceutical company focused on developing innovative
treatments for cancer patients, including Phase 1-stage MNPR-101-Zr
for imaging advanced cancers, Phase 1-stage MNPR-101-Lu and late
preclinical-stage MNPR-101-Ac225 for the treatment of advanced
cancers, as well as early development stage programs against solid
cancers. For more information, visit: www.monopartx.com.
CONTACT:
Monopar Therapeutics Inc. Investor
Relations Karthik Radhakrishnan Chief Financial Officer
karthik@monopartx.com
Follow Monopar on social media for updates:
Twitter: @MonoparTx LinkedIn: Monopar Therapeutics
Grafico Azioni Monopar Therapeutics (NASDAQ:MNPR)
Storico
Da Ott 2024 a Nov 2024
Grafico Azioni Monopar Therapeutics (NASDAQ:MNPR)
Storico
Da Nov 2023 a Nov 2024
